Transplantation Proceedings
Volume 36, Issue 5 , Pages 1481-1482, June 2004

Living donor liver transplantation for end-stage hepatitis C☆

  • Y Sugawara

      Affiliations

    • Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    • Corresponding Author InformationAddress reprint requests to Y. Sugawara, MD, Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    • ,
  • J Kaneko

      Affiliations

    • Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    • ,
  • N Akamatsu

      Affiliations

    • Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    • ,
  • Y Kishi

      Affiliations

    • Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    • ,
  • S Hata

      Affiliations

    • Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    • ,
  • N Kokudo

      Affiliations

    • Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    • ,
  • M Makuuchi

      Affiliations

    • Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

Abstract 

Living donor liver transplantation is important for patients with end-stage viral hepatitis because of the shortage of organs from deceased donors. However, preliminary results indicate that living liver donation might be disadvantageous for hepatitis C virus–positive patients. Twenty-seven patients who underwent living donor liver transplantation for hepatitis C virus cirrhosis preemptively received antiviral therapy using interferon-alpha2b and ribavirin, which was started an average of 32 days after the operation and continued for at least 6 months thereafter. The serum hepatitis C virus RNA became negative in the 8 of 16 patients with more than 1 year follow-up. The cumulative 3-year patient survival was 85%, which was comparable to that of hepatitis C virus negative patients (n = 93; 90%). Preemptive antiviral therapy after transplantation may be necessary for satisfactory results after living donor liver transplantation.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ Supported by a Grant-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, Public Trust Fund for the Promotion of Surgery, Welfide Medical Research Foundation, Mitsui Life Social Welfare Foundation, and a Grant-in-aid for Research on Human genome, Tissue engineering, Food biotechnology, Health sciences research grants, Ministry of Health, Labor and Welfare of Japan.

PII: S0041-1345(04)00508-1

doi:10.1016/j.transproceed.2004.04.076

Transplantation Proceedings
Volume 36, Issue 5 , Pages 1481-1482, June 2004

Article Tools